Compile Data Set for Download or QSAR
Report error Found 288 Enz. Inhib. hit(s) with all data for entry = 8614
TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403752((2S,5R)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-bip...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403763((2S,5R)-5-(2-chlorophenyl)-1-(2'-methyl-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403764((2S,5R)-1-(3-((4-chlorobenzyl)oxy)-5-methoxybenzoy...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403767((2S,5R)-5-(2-chlorophenyl)-1-(2'-fluoro-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403773((2S,5R)-5-(2-chlorophenyl)-1-(4'-methyl-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403786((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-phenetho...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403787((2S,5R)-1-([1,1'-biphenyl]-4-carbonyl)-5-(2-chloro...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403788((2S,5R)-5-(2-chlorophenyl)-1-(3-(3,3-diphenylpropo...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403789((2S,5R)-5-(2-chlorophenyl)-1-(3'-fluoro-[1,1'-biph...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403790((2S,5R)-5-(2-chlorophenyl)-1-(3'-methyl-[1,1'-biph...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403791((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-((4-(met...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403792((2S,5R)-5-(2-chlorophenyl)-1-(3'-methoxy-[1,1'-bip...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403793((2S,5R)-5-(2-chlorophenyl)-1-(3,5-dimethoxybenzoyl...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403794((2S,5R)-5-(2-chlorophenyl)-1-(4-(phenoxymethyl)ben...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403795((2S,5R)-5-(2-chlorophenyl)-1-(4-((2-fluorobenzyl)o...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403796((2S,5R)-1-(3-chloro-5-methoxybenzoyl)-5-(2-chlorop...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403797((2S,5R)-5-(2-chlorophenyl)-1-(4'-fluoro-[1,1'-biph...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403798((2S,5R)-5-(2-chlorophenyl)-1-(4-phenethoxybenzoyl)...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403799((2S,5R)-5-(2-chlorophenyl)-1-(chroman-3-carbonyl)p...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403800((2S,5R)-5-(2-chlorophenyl)-1-(3,5-diethoxybenzoyl)...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403801((2S,5R)-5-(2-chlorophenyl)-1-(3-phenethoxybenzoyl)...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403802((2S)-1-([1,1'-biphenyl]-4-carbonyl)-4-benzyl-5-phe...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403804((2S,5R)-5-(2-chlorophenyl)-1-(2,2-difluorobenzo[d]...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM408503(US10358416, Compound 27 | (2S,5R)-5-(2-chlorophen...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403805((2S,5R)-5-(2-chlorophenyl)-1-(6-phenylnicotinoyl)p...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM408505(US10358416, Compound 31 | (2S,5R)-5-(2-chloropheny...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM408506(US10358416, Compound 32 | (2S,5R)-5-(2-chlorophen...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM408507(US10358416, Compound 33 | (2S,5R)-5-(2-chloropheny...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403809((2S,5R)-5-(2-chlorophenyl)-1-(1-(4-methoxyphenyl)-...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403810((2S,5R)-5-(2-chlorophenyl)-1-(4-isopropoxybenzoyl)...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403811((2S,5R)-5-(2-chlorophenyl)-1-(3-((3,5-dimethylisox...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403812((2S,5R)-5-(2-chlorophenyl)-1-(3-methyl-5-(trifluor...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403813((2S,5R)-1-(3-(benzyloxy)benzoyl)-5-(2-chlorophenyl...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403814((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxybenzoyl)pyr...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403815((2S,5R)-5-(2-chlorophenyl)-1-(2-phenylpyrimidine-5...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403816((2S,5R)-5-(2-chlorophenyl)-1-(4-(trifluoromethoxy)...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403817((2S,5R)-5-(2-chlorophenyl)-1-(4-(5-cyclopropyl-1,2...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403818(4-((2S,5R)-2-carboxy-5-(2-chlorophenyl)pyrrolidine...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403819((2S,5R)-5-(2-chlorophenyl)-1-(4-phenylbutanoyl)pyr...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403820((2S,5R)-1-([1,1'-biphenyl]-4-carbonyl)-5-(3-chloro...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM408520(US10358416, Compound 48 | (2S,5R)-5-(2-chlorophen...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403826((2S,5S)-5-(2-chlorophenyl)-1-(3-methoxybenzoyl)pyr...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403828((2S,5R)-5-(2-chlorophenyl)-1-(3-phenylpropanoyl)py...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403829((2S,5S)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-bip...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403831((2S,5R)-1-(2-([1,1'-biphenyl]-4-yl)acetyl)-5-(2-ch...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403832((2R,5S)-1-([1,1'-biphenyl]-4-carbonyl)-5-phenylpyr...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403834((2S,5R)-5-(2-chlorophenyl)-1-(6-(2-chlorophenyl)ni...)
Affinity DataEC50: <200nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403835((2S,5R)-5-(2-chlorophenyl)-1-(6-(2-methoxyphenyl)n...)
Affinity DataEC50:  600nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403836((2S,5R)-5-(2-chlorophenyl)-1-(2-(2-chlorophenyl)py...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403837((2S,5R)-5-(2-chlorophenyl)-1-(4-(pyridin-2-yl)benz...)
Affinity DataEC50: >1.00E+3nMAssay Description:The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM NaCl, 10 μg/ml saponin, 30 mM of MgCl2, 10 μM of GDP, 5 μg membra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 288 total ) | Next | Last >>
Jump to: